UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **March 6, 2013**

ADVAXIS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

00028489	**02-0563870**
(Commission File Number)	(IRS Employer Identification Number)

305 College Road East
Princeton, New Jersey 08540
(Address of principal executive offices)

Registrant's telephone number, including area code: **(609) 452-9813**

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On March 6, 2013, Advaxis, Inc. (the "Company") held a conference call and webcast to discuss the Company's 2013 business outlook. A copy of the slides presented as part of the webcast is filed as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Presentation of Advaxis, Inc., dated as of March 6, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 7, 2013

Advaxis, Inc.

By: /s/ Mark J. Rosenblum
Mark J. Rosenblum
Chief Financial Officer and Secretary

EXHIBIT INDEX

Exhibit No.	**Document Description**
99.1	Presentation of Advaxis, Inc., dated as of March 6, 2013.

Exhibit 99.1

Developing the Next Generation of Cancer Immunotherapies™



2013 Business Outlook Conference Call and Webcast

Thomas A. Moore, CEO
Advaxis, Inc.
(OTC BB: ADXS)

ADVAXIS

Forward Looking Statements

This presentation contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at http://www.sec.gov.

The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

ADVAXIS

Thomas A. Moore

Chairman and CEO

Advaxis Management Team

Thomas A. Moore, *Chairman / CEO*

25 years experience in healthcare, executive management and business development. As CEO of Nelson Communications, engineering the sale of the company to *Publicis* Group for $246 million. President of Procter & Gamble's (NYSE: PG) worldwide healthcare products business.

Mark J. Rosenblum, *CFO, Secretary, Senior VP*

25 years experience in accounting and financial leadership. VP, Chief Accounting Officer of Wellman, Inc., a $1.2Bn chemical company; CFO and Secretary, HemoBioTech, Inc.

Robert Petit, Ph.D., *VP Clinical Operations & Medical Affairs*

25+ years experience in oncology drug development. US medical strategy lead for Yervoy® (ipilimumab) program at Bristol Myers Squibb (NYSE: BMY) as the Director of Medical Strategy for new oncology products and Director of Global Clinical Research. VP of Clinical Development at MGI Pharma and Aesgen, Inc.

Daniel J. O'Connor, Esq., *Senior VP, Chief Legal and Business Development Officer*

15 years of executive, legal, and regulatory experience in the biopharmaceutical industry with ImClone Systems, PharmaNet and Bracco Diagnostics. As SVP/ GC at ImClone, played a key role in extensive licensing negotiations, paving the way for company to be sold to Eli Lilly in 2008.

Chris French, *Executive Director of Medical Affairs*

20 years of science research and pharmaceutical experience in drug development in start-up, midsize and large pharmaceutical companies. She has held management positions in medical affairs, regulatory affairs, business development and scientific communications, most recently as US Director of Oncology Scientific Communications at Bristol Myers Squibb.

ADVAXIS

Advaxis Overview

- **Advaxis** is headquartered in Princeton, NJ
- **Dr. Yvonne Paterson** developed technology at the University of Pennsylvania in the early 1990s and licensed exclusively to Advaxis in 2002
- **Advaxis proprietary platform: 2 key elements:**
  - **Live attenuated *Listeria monocytogenes* (*Lm*):**
    - Attenuation is 10,000 to 100,000 times to enhance safety
    - Stimulates a balanced and comprehensive cellular immune response to *Lm*
    - PAMP driven response drives a more complex immune reaction
    - *Lm* is further engineered to manufacture and secrete antigen/t-LLO fusions
  - **Antigen proteins fused to truncated LLO (tLLO) and manufactured/secreted by *Lm***
    - tLLO drives its own PAMP response
    - Overcomes tumor protection mechanisms inside the tumor- NOT systemically
- Current constructs target HPV-associated cancers and dysplasia, prostate cancer, HER2 over expressing cancers, with several other antigens in R&D

ADVAXIS

5 Ongoing Studies with ADXS-HPV

- Phase 1 refractory cervical cancer (15 patients)*
- Phase 2 refractory cervical cancer (110 patients)**
- Phase 2 refractory cervical cancer (67 patients)
- Phase 2 cervical neoplastic dysplasia (CIN) 2/3 (120 patients)**
- Phase 1/2 head and neck cancer (27 patients)
- Phase 1/2 anal cancer (25 patients)

results published, ** preliminary data reported

ADVAXIS

Advaxis Clinical Pipeline

	Clinical Pipeline			
Construct	Indication	Pre	Phase 1	Phase 2
ADXS-HPV	Cervical Cancer, India			
ADXS-HPV	Cervical Cancer, US, GOG			
ADXS-HPV	CIN 2/3, US			
ADXS-HPV	Head & Neck Cancer, CRUK			
ADXS-HPV	Anal Cancer, BrUOG			
ADXS-PSA	Prostate Cancer			
ADXS-cHER2	Canine Osteosarcoma, Penn			

Proprietary Platform Can Create Multiple Product Candidates

Lm-LLO Immunotherapy	Tumor Antigen	Tumor model	Reference
ADXS11-001	HPV16- E7	TC-1	Gunn et al 2001
ADXS31-142	Prostate Specific antigen	TRAMPC1 /PSA	Shahabi et al. 2008, Wallecha et al. 2009
ADXS31-164	Her2/neu Chimera	NT-2 Breast/Transgenic Her2	Seavey et al 2009 Shahabi et al 2011
***Lm*-LLO-HMW-MAA**	HMW-MAA , C-terminus fragment	NT-2 Breast/Transgenic Her2/B16F10-HMW-MAA	Maciag et al 2008
***Lm*-LLO-ISG15**	ISG15	4T1 breast tumor model	Wood et al 2012
***Lm*-LLO-CD105**	Endoglin	NT-2 Breast/Transgenic Her2	Wood et al 2011
***Lm*-LLO-flk**	VEGF	NT-2 Breast/Transgenic Her2	Seavey et al 2009
Bivalent Therapy	Her-2-chimera/HMW-MAA-C	NT-2 Breast/Transgenic Her2	Ongoing

- ***Lm* can secrete extracellular, intracellular or transmembrane regions**
- ***Lm* can express proteins with different functions such as enzymes, receptors, transcription factors, etc.**
- **Chimeric molecules can be created by the fusion of epitope rich fragments**

ADVAXIS


ViE
Vaccine Industry Excellence
AWARDS
2012 Winner
Best Therapeutic Vaccine
(approved or in development)

ADVAXIS

2012 Achievements

- Secured access to $10M committed equity line
- Eliminated ~ 80% of debt
- Achieved proof of concept for ADXS-HPV
- Bolstered existing management team

Overarching 2013 Objectives

1. Continue to advance lead ADXS-HPV toward registration development program
2. Continue to significantly strengthen financial position

Daniel J. O'Connor

Senior Vice President

Chief Business Development and Legal Officer

Phrma.org 2012 Report Medicines in Development for Cancer

Source http://www.phrma.org/sites/default/files/1000/phrmamedicinesindevelopmentcancer2012.pdf



13

ADVAXIS

Phrma.org 2012 Report Industry Sponsored Cervical Cancer Drug Development

Source http://www.phrma.org/sites/default/files/1000/phrmamedicinesindevelopmentcancer2012.pdf

Cervical cancer			
Product Name	Sponsor	Indication	Development Status
ADXS-HPV	**Advaxis** ***Princeton, NJ***	**cervical cancer, cervical intraepithelial neoplasia**	**Phase 2**
PM-00104	PharmaMar *Madrid, Spain*	(see also sarcoma, other)	Phase 2
PV701 (replication-competent oncolytic virus)	Wellstat Biologics *Gaithersburg, MD*	(see also colorectal)	Phase 2
Terameprocol	Erimos Pharmaceuticals *Houston, TX*	cervical intraepithelial neoplasia (intravaginal) (see also brain, head/neck, solid tumors, other)	Phase 2
V503 (HPV virus-like particle (VLP) vaccine)	Merck *Whitehouse Station, NJ*	prevention of cervical cancer, prevention of vulvovaginal cancer	Phase 3
V505 (HPV vaccine)	Merck *Whitehouse Station, NJ*	prevention of cervical cancer	Phase 2 completed
verpasep caltespen (cancer vaccine)	Akela Pharma *Austin, TX*	cervical intraepithelial neoplasia	Phase 1 completed
VGX-3100 (DNA cancer vaccine)	Inovio Pharmaceuticals *Blue Bell, PA*	cervical intraepithelial neoplasia	Phase 2

ADVAXIS

Growth in HPV mediated cancers… drives even wider potential for ADXS-HPV



~527,000
Incidence per year
Worldwide
(12,000 US)

ADVAXIS

Growth in HPV mediated cancers… drives even wider potential for ADXS-HPV



Robert Petit, Ph.D.

VP Clinical Operations & Medical Affairs

Disease burden is concentrated:

~50% of cervical cancer burden exists in India, China & South America

Country	Cervical Incidence	% of World	Cum % Market
India	134420	25.5%	25.5%
China	75434	14.3%	39.8%
S. America	47600	9.0%	48.8%
E. Africa	31500	6.0%	54.8%
E. Europe	31000	5.9%	60.7%
W. Africa	29000	5.5%	66.2%
Bangladesh	17686	3.4%	69.5%
C. America	15600	3.0%	72.5%
Indonesia	13762	2.6%	75.1%
N. America	12400	2.4%	77.4%
Pakistan	11688	2.2%	79.6%
Thailand	9998	1.9%	81.5%
W. Europe	9300	1.8%	83.3%
Japan	8894	1.7%	85.0%
S. Europe	8600	1.6%	86.6%
M. Africa	8200	1.6%	88.2%
S. Africa	6500	1.2%	89.4%

ADVAXIS

Cervical Cancer is a Worldwide Problem

- According to WHO, ~ 630 million people are infected with one of the over 100 strains of HPV
- Global prevalence of clinically pre-malignant HPV infections to be between 28 to 40 million women
- Approximately 500,000 newly diagnosed cases of cervical cancer
- Cervical cancer ranks as the 2nd leading cause of cancer death of women in the world
- About 11.4% of women in the general population are estimated to harbor cervical HPV infection

ADVAXIS

ADXS-HPV Lead Indication:
Phase 2 Cervical Cancer Study +/- Cisplatin Study Design



* Low dose cisplatin: 40mg/m^2

ADVAXIS

Preliminary Phase 2 Data Show Encouraging Survival Compared to Historical Controls

ADXS-HPV
Preliminary Landmark Survival Data
(as of October 22, 2012)

	6 mo.	9 mo.	12 mo.	18 mo.
# Alive/N	71/109	39/88	23/70	6/36
% Survival	65%	44%	33%	17%

Published Phase 2 single agent trials report 12 months survival of 0-22%*

**NCCN Guidelines:*
Plaxe SC, et. al., 2002, Cancer Chemother Pharmacol; 50: 151-4.
Garcia AA, et. al., 2007, Am J Clin Oncol; 30: 428-431.

ADVAXIS

Proof of Concept Achieved

- ADXS-HPV is emerging as an active agent in recurrent/refractory cervical cancer with a predictable safety profile
- Apparent prolonged survival, durable complete and partial tumor reductions, as well as stabilization of disease have been observed with ADXS-HPV treatment
- ADXS-HPV can be safely combined with chemotherapy

ADVAXIS

2013 Clinical and Regulatory Objectives

- Analyze Phase 2 data and work to optimize dose and schedule
- Proceed with clinical plan with the advice and collaboration of global thought leaders in cervical cancer
- Finalize clinical plan and consult with regulatory authorities to advance ADXS-HPV to registrational trials

ADVAXIS

Mark J. Rosenblum

Senior Vice President
Chief Financial Officer

Financial Overview

Exchange / Ticker	OTC BB: ADXS
Cash Raised Since Inception - approximately	$40M
Committed Equity Financing Facility	$10M
Monthly Cash Spend (including clinical)	$600K
Debt non-affiliate at Y/E 2012 Down from $9M Year Ago	<$2.0M
Common Stock Outstanding	515.1M
Warrants	100M
Options	44.8M
Market Capitalization – March 5, 2013	$55M
Avg. Daily Volume (3 months)	5.1M
Public Float	495M

ADVAXIS

Clinical Milestones 2013

Early Q2 2013

- Announce CIN 2/3 mid-dose Cohort 2 data

Q2 2013

- Announce 12-month survival data from India study

H2 2013

- Announce final Phase 2 cervical cancer results
- Initiate the Phase 2 High-dose Cohort 3 CIN 2/3

By end of 2013

- Complete the safety portion of the ADXS-cHER2 Phase 1/2 canine study
- Report preliminary data from canine study

H1 2014

- File IND with the FDA for ADXS-PSA

ADVAXIS

Thank You

Advaxis Inc. (OTC BB: ADXS)

305 College Road East
Princeton, NJ 08540
609.452.9813
ir@advaxis.com
www.advaxis.com

Developing the Next Generation of Cancer Immunotherapies™

ADVAXIS